Skip to main content

Filter by

Filter results by:
Found 60 clinical trials.

Clinical Trials List

Interventional
Not yet recruiting

Investigating the Experience of Living With Down Syndrome and Obstructive Sleep Apnea Syndrome (Stage 2)

Gender: all
Age: 6 Years to 18 Years

Trial Description

Determine the efficacy of family-informed intervention (INT) vs standard clinical care over a period of twelve months in children with obstructive sleep apnea and Down Syndrome.
View Trial
Observational
Not yet recruiting

OHRQoL and Parental Perception in a Group of Children and Adolescents With Down Syndrome: A Cross

Gender: all
Age: 6 Years to 14 Years

Trial Description

The aim of the study is to evaluate Oral Health related quality of life of children and adolescents with down syndrome and Parental Perception, knowledge and Attitude on oral health conditions of children and adolescents with down syndrome.
View Trial
Interventional
Not yet recruiting

A Study of ACI-24 in Adults With Down Syndrome

Gender: all
Age: 40 Years to 50 Years

Trial Description

This study is a prospective multicenter, placebo-controlled, double-blind, randomized study to assess the effect of one dose ACI-24 versus placebo over a 74-week treatment period and 26-week safety follow-up period.
View Trial
Observational
Not yet recruiting

Pulmonary Health in Children With Down Syndrome

Gender: all
Age: 3 Years to 18 Years

Trial Description

The goal of the study is to learn more about tests that can assess lung health in children with Down syndrome.
View Trial
Interventional
Not yet recruiting

Medications for Obstructive Sleep Apnea In Children With Down Syndrome

Gender: all
Age: 6 Years to 17 Years

Trial Description

This is a randomized, double blind, cross-over study of the combination of atomoxetine and oxybutynin (ato-oxy) in children with DS and OSA documented by polysomnography (PSG). Participants will receive high dose ato-oxy for four weeks as well as low dose ato-oxy for four weeks in random order. During the high dose ato-oxy period, participants will take 5 mg oxybutynin and 0.5mg/kg/day (max 40 mg) atomoxetine nightly for one week. Atomoxetine dose will then be increased to 1.2 mg/kg/day (max 80 mg). During the low dose ato-oxy period, participants will take 5 mg oxybutynin and 0.5mg/kg/day (max 40 mg) atomoxetine. Dosing of the study treatment will occur approximately 30 minutes prior to bedtime.
View Trial
...
Close Menu